27 57

Cited 0 times in

Serum fibrosis index-based risk score predicts hepatocellular carcinoma in untreated patients with chronic hepatitis B

Authors
 Lilian Yan Liang  ;  Hye Won Lee  ;  Vincent Wai-Sun Wong  ;  Terry Cheuk-Fung Yip  ;  Yee-Kit Tse  ;  Vicki Wing-Ki Hui  ;  Grace Chung-Yan Lui  ;  Henry Lik-Yuen Chan  ;  Grace Lai-Hung Wong 
Citation
 CLINICAL AND MOLECULAR HEPATOLOGY, Vol.27(3) : 499-509, 2021-07 
Journal Title
CLINICAL AND MOLECULAR HEPATOLOGY
ISSN
 2287-2728 
Issue Date
2021-07
Keywords
Carcinoma, Hepatocellular ; Fibrosis ; Hepatitis B, Chronic ; Surveillance
Abstract
Background/aims: Serum fibrosis scores comprised of common laboratory tests have high utility to assess severity of liver fibrosis. We aimed to derive and validate a hepatocellular carcinoma (HCC) risk score based on serum fibrosis scores to predict HCC in treatment-naïve chronic hepatitis B (CHB) patients.

Methods: Fifteen thousand one hundred eighty-seven treatment-naïve adult CHB patients were identified to form the training cohort in this retrospective study. Individual fibrosis score was included to construct a new HCC prediction score. The score was externally validated in an independent treatment-naïve Korean CHB cohort.

Results: 180/15,187 patients (1.2%) in training cohort and 47/4,286 patients (1.1%) in validation cohort developed HCC during a mean follow-up of 52 and 50 months, respectively. The newly developed HCC risk score, Liang score, is composed of gender, age, hepatitis B virus DNA, fibrosis-4 (FIB-4) index, and ranges from 0 to 22. Area under the time-dependent receiver operating characteristic curve of Liang score was 0.79 (95% confidence interval, 0.70-0.89). A cutoff value of nine provided an extremely high negative predictive value of 99.9% and high sensitivity of 90.0% at 5 years in the validation cohort. Patients with Liang score ≤9 had HCC incidence <0.2% per year in both training and validation cohorts, in whom HCC surveillance might be exempted.

Conclusion: A novel HCC risk score, Liang score, based on FIB-4 index, is applicable and accurate to identify treatment-naïve CHB patients with very low risk of HCC to be exempted from HCC surveillance.
Files in This Item:
T202103007.pdf Download
DOI
10.3350/cmh.2020.0333
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Lee, Hye Won(이혜원) ORCID logo https://orcid.org/0000-0002-3552-3560
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/184430
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links